A consideration of PPAR-γ ligands with respect to lipophilicity: Current trends and perspectives

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 413-417

  Giaginis, Costas ^a   Theocharis, Stamatios ^a   Tsantili Kakoulidou, Anna ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Binding affinity; Lipophilicity; PPAR ligands; Structure activity relationships; Thiazolidinediones; Transactivation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

BINDING AFFINITY; BIOLOGICAL ACTIVITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; LIGAND BINDING; LIPOPHILICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

ANIMALS; HUMANS; LIGANDS; LIPID METABOLISM; PPAR GAMMA; TRANS-ACTIVATION (GENETICS);

EID: 34147107149     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.413     Document Type: Editorial

References (35)

1. NOLTE RT, WISELY GB, WESTIN S et al.: Ligand binding and co-activator assembly of the peroxisome proliferators activated receptor-γ. Nature (1998) 395:137-143.
2. WILLSON TM, BROWN PJ, STRENBACH DD, HENKE BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43:527-550.
3. BRAISSANT O, FOUFELLE F, SCOTTO C, DAUÇA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β- and -γ in the adult rat. Endocrinology (1996) 137:354-366.
4. LEMBERGER T, BRAISSANT O, JUGE-AUBRY C et al.: PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann. NY Acad. Sci. (1996) 804:231-251.
5. RIZZO G, FIORUCCI S: PPARs and other nuclear receptors in inflammation. Curr. Opin. Pharm. (2006) 6:1-7.
6. THEOCHARIS S, MARGELI A, VIELH P, KOURAKLIS G: Peroxisome proliferator activated receptor-γ as cell cycle modulators. Cancer Treat. Rev. (2004) 30:545-554.
7. PATEL CB, DE LEMOS JA, WYNE KL, MCGUIRE DK: Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR γ agonism. Diab. Vast. Dis. Res. (2006) 3:65-71.
8. WILLSON TM, LAMBERT MH, KLIEWER SA: Peroxisome proliferator-activated receptor γ and metabolic disease. Ann. Rev. Biochem. (2001) 70:341-367.
9. OGUCHI M, WADA K, HONNA H et al.: Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones. J. Med Chem. (2000) 43:3052-3066.
10. SCHOPFER GJ, LIN Y, BAKER PRS et al.: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc. Natl. Acad. Sci. USA (2005) 102:2340-2345.
11. LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-proliferator-activated receptor γ (PPARγ). J. Biol. Chem. (1995) 270:12953-12956.
12. HENKE B. BLANCHARD SB, BRACKEEN MF et al.: N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med Chem. (1998) 41:5020-5036.
13. COLLINS JL, BLANCHARD SB, BOSWELL EG et al.: N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem. (1998) 41:5037-5054.
14. LEHMANN JM, LENHARD JM, OLIVER BB, RINGOLD GM, KLIEWER SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1997) 272:3406-3410.
15. WYSOWSKI DK, ARMSTRONG G, GOVERNALE L: Rapid increase in the use of oral antidiabetic drugs in the United States, 1990 - 2001. Diabetes Care (2003) 26:1852-1855.
16. WILLSON TM, COBB JE, COWAN DJ et al.: The structure-activity relationship between peroxisome proliferator-activated receptor γ. Agonism and the anti-hyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39:665-668.
17. FEINSTEIN DL, SPANGOLO A, AKAR C et al.: Receptor-independent action of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. (2005) 70:177-188.
18. KULKARNI SS, GEDIYA LK, KULKARNI VM: Three dimensional quantitative structure-activity relationships (3-D QSAR) of antihyperglycemic agents. Bioorg. Med. Chem. (1999) 7:1475-1485.
19. IWATA Y, MIYAMOTO S, TAKAMURA M, YANAGISAWA H, KASUYA A: Interaction between peroxisome proliferator-activated receptor γ and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. J. Mol. Graph. Model. (2001) 19:536-542.
20. PAGLIARA A, CARRUPT P-A, CARON G, GAILLARD P, TESTA B: Lipophilicity profiles of ampholytes. Chem. Rev. (1997) 97:3385-3400.
21. TAKACS-NOVAK K, JÓZAN M, SZÁS G: Lipophilicity of amphoteric molecules expressed by the true partition coefficient. Int. J. Pharm (1995) 113:47-55.
22. PISTOS C, TSANTILI-KAKOULIDOU A, KOUPPARIS M: Investigation of the retention/pH profile of zwitterionic fluoroquinolones by means of reversed phase and ion-pair high performance liquid chromatography. J. Pharm. Biomed. Anal. (2005) 39:438-443.
23. 1-receptor antagonist. J. Med. Chem. (1998) 41:853-863.
24. PLISKA V, TESTA B, VAN DE WATERBEEMD H: Lipophilicity in drug action and toxicology. In: Methods and Principles in Medicinal Chemistry. (Volume 4). Mannhold R, Kubinyi H, Timmerman H (Eds), Wiley VCH, Weinheim, Germany (1996).
25. HANSCH C, BJORKROTH JP, LEO A: Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. (1987) 76:663-687.
26. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. (1997) 23:3-25.
27. MANNHOLD R: Calculation of lipophilicity. A classification of method. In: Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies. Testa B, Krämer SD, Wunderli-Allenspach H, Folkers G (Eds), Verlag Helvetica Chimica Acta, Wiley VCH, Zürich, Switzerland (2006):333-352.
28. VRAKAS D, TSANTILI-KAKOULIDOU A, HADJIPAVLOU-LITINA D: Exploring the consistency of logP estimation for substituted coumarins, Quant. Struct. - Act. Relat. (2003) 22:622-629.
29. DELLIS D, GIAGINIS C, TSANTILI-KAKOULIDOU A: Physicochemical profile of nimesulide. Exploring the interplay of lipophilicity, solubility and ionization. J. Pharm. Biomed. Anal. (In Press).
30. LIAO C, XIE A, ZHOU J, SHI L, LI Z, LU XP: 3D QSAR studies on peroxisome proliferator-activated receptor γ agonists using CoMFA and CoMSIA. J. Mol. Model. (2004) 10:165-177.
31. KUROGI Y: Three-dimensional quantitative structure-activity relationship (3D-QSAR) of antidiabetic thiazolidinediones. Drug Des. Discov. (1999) 16:109-118.
32. RATHI L, KASHAW SK, DIXIT A, PANDEY G, SAXENA AK: Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPAR agonists. Bioorg. Med. Chem. (2004) 12:63-69.
33. RUCKER C, SCARSI M, MERINGER M: 2D QSAR of PPARγ agonist binding and transactivation. Bioorg. Med. Chem. (2006) 14:5178-5195.
34. OPREA TI: Property distribution of drug-related chemical databases. J. Comput-Aided Mol. Des. (2000) 14:251-264.
35. GIAGINIS C, THEOCHARIS S, TSANTILI-KAKOULIDOU A: Investigation of the lipophilic behavior of the PPARγ ligands thiazolidinediones as an important issue for their action. Drugs Fut. (2006) 31:A44.